Core Viewpoint - The Hang Seng Healthcare Index has declined by 3.3% this week, underperforming the market, with a slight decrease in domestic investors' holdings of pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased [1] Group 1: Market Performance - The Hang Seng Healthcare Index has experienced a cumulative drop of 3.3% this week [1] - Domestic investors' holdings of pharmaceutical stocks via the Hong Kong Stock Connect have slightly decreased [1] - Foreign investment in the sector has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 2: Investment Recommendations - The company suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC in the pharmaceutical business development this year [1] - The sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 3SBio (01530), Hutchison China MediTech (00013), and Genscript Biotech (02595) [1] - CXO segment leaders like WuXi AppTec (02268) may benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics may see regulatory uncertainties easing along with positive policy expectations [1]

Investment Rating - The industry investment rating is "Outperform the Market" [29] Core Insights - AbbVie reported a total revenue of $44.542 billion for the first three quarters of 2025, representing an 8.0% year-over-year growth, with Q3 revenue reaching $15.776 billion, up 9.1% [5][9] - The strong performance is primarily driven by two key immunology drugs, Rinvoq and Skyrizi, which have seen significant sales growth [5][19] - AbbVie has raised its full-year guidance, indicating positive momentum across its business segments, including immunology, neuroscience, and oncology [5][9] Summary by Sections Part 1: Financial Overview and Key Events - AbbVie’s revenue contributions from major segments include Immunology at $21.780 billion (+12.3%), Neuroscience at $7.806 billion (+20.3%), and Oncology at $4.991 billion (+2.6%) for the first three quarters of 2025 [5][9] - The company has advanced several projects into regulatory approval and submission phases, including Rinvoq for various indications [10][12][23] Part 2: Core Product Sales Analysis - Rinvoq generated $5.930 billion in revenue for the first three quarters of 2025, a 43.3% increase, while Skyrizi achieved $12.556 billion, growing 58.1% [19][17] - The combined sales of Rinvoq and Skyrizi reached $6.9 billion in Q3 alone, establishing them as leading products in the immunology sector [19][27] Part 3: Future Pipeline Milestones - In 2026, AbbVie anticipates five drug approvals, four regulatory submissions, and five Phase III data readouts, including Rinvoq for vitiligo and alopecia areata [22][23] - Key upcoming regulatory events include submissions for Tavapadon for Parkinson's disease and Venclexta for higher-risk MDS [22][23] Part 4: Investment Recommendations - The strong sales of Skyrizi and Rinvoq are expected to continue driving AbbVie's growth, with Skyrizi projected to become a "super blockbuster" in 2024 [27] - Investors are advised to monitor domestic companies targeting the IL-23 pathway, such as Innovent Biologics and Kintor Pharmaceutical [27]